Baidu
map

研究支持肠癌手术后化疗减半

2018-03-29 MedSci MedSci原创

根据《柳叶刀肿瘤学》(Lancet Oncology)上发表的一项新研究,一些接受了肠癌手术治疗的患者可能只需要3个月的治疗,而不是目前的6个月。国际临床试验由NIHR和MRC合作伙伴资助,并由格拉斯哥的英国癌症研究英国临床试验部门领导,评估了为期3个月的奥沙利铂/氟嘧啶联合化疗对结直肠癌的疗效与标准六个月方案的疗效。三年后,接受三个月方案的患者中有76.7%是无病的,而在六个月内接受治疗的患者中


根据《柳叶刀肿瘤学》(Lancet Oncology)上发表的一项新研究,一些接受了肠癌手术治疗的患者可能只需要3个月的治疗,而不是目前的6个月。

国际临床试验由NIHR和MRC合作伙伴资助,并由格拉斯哥的英国癌症研究英国临床试验部门领导,评估了为期3个月的奥沙利铂/氟嘧啶联合化疗对结直肠癌的疗效与标准六个月方案的疗效。
三年后,接受三个月方案的患者中有76.7%是无病的,而在六个月内接受治疗的患者中有77.1%的患者是无病的。在治疗时间较短的情况下也报道了更少的副作用和更好的生活质量。

研究人员说,数据还显示周围神经病变减少--奥沙利铂的一种常见副作用--在治疗方案较短的患者中。

"每年约2,500名患者目前接受长达六个月的术后化疗。将化疗持续时间缩短至三个月每位患者将节省NHS 5,000英镑 - 总计每年为NHS节省1,250万英镑," 英国南安普顿大学医院NHS基金会信托和名誉副教授、英国南安普顿大学医院顾问医学肿瘤学专家Tim Iveson博士指出。

"这项研究将为个别患者带来直接好处,避免药物不必要的副作用,并为NHS节省成本。这可能会导致肠癌患者接受治疗方式发生重大变化,"NIHR评估,试验和研究主任Tom Walley教授补充说。


此文系梅斯医学(MedSci)原创整理编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1976049, encodeId=409d19e60495b, content=<a href='/topic/show?id=e796610430e' target=_blank style='color:#2F92EE;'>#术后化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61043, encryptionId=e796610430e, topicName=术后化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Tue Jan 08 20:19:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301054, encodeId=edbf30105485, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Fri Mar 30 06:42:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300967, encodeId=04cb30096e54, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Mar 29 23:37:56 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1976049, encodeId=409d19e60495b, content=<a href='/topic/show?id=e796610430e' target=_blank style='color:#2F92EE;'>#术后化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61043, encryptionId=e796610430e, topicName=术后化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Tue Jan 08 20:19:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301054, encodeId=edbf30105485, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Fri Mar 30 06:42:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300967, encodeId=04cb30096e54, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Mar 29 23:37:56 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-30 owlhealth

    不错耶.学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1976049, encodeId=409d19e60495b, content=<a href='/topic/show?id=e796610430e' target=_blank style='color:#2F92EE;'>#术后化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61043, encryptionId=e796610430e, topicName=术后化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Tue Jan 08 20:19:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301054, encodeId=edbf30105485, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Fri Mar 30 06:42:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300967, encodeId=04cb30096e54, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Mar 29 23:37:56 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-29 惠映实验室

    学习了.谢谢分享.

    0

Baidu
map
Baidu
map
Baidu
map